Belite Bio (NASDAQ:BLTE) Stock Breaks Above 200 Day Moving Average - Time to Sell?

Key Points

• Belite Bio shares rose 9% and moved above their 200-day moving average, trading as high as $170.89 and last quoted at $169.96.
• The FDA accepted the company’s tinlarebant application for priority review for Stargardt disease. Belite also reported a smaller-than-expected quarterly loss of $0.60 per share, though its net loss was $30.3 million.
• Analysts’ consensus rating is “Moderate Buy,” with an average price target of $227.40, but executives have recently sold shares and the company remains loss-making.

Shares of Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE - Get Free Report) crossed above its two hundred day moving average during trading on Thursday. The stock has a two hundred day moving average of $160.25 and traded as high as $170.89. Belite Bio shares last traded at $169.96, with a volume of 495,924 shares traded.

Latest Belite Bio News

These are some of the BLTE news items that stood out recently:

• Positive Sentiment: The FDA accepted Belite Bio’s tinlarebant NDA for priority review, a significant step toward potential approval for Stargardt disease. The company described tinlarebant as a potential first treatment for the condition, making the regulatory timeline a key catalyst. Belite Bio Q3 2026 Earnings Call Highlights
• Positive Sentiment: Belite reported Q3 2026 earnings per share of ($0.60), better than the consensus estimate of ($0.79). The earnings beat may support investor sentiment, although the company remains loss-making. Belite Bio quarterly earnings results
• Negative Sentiment: The company recorded a quarterly net loss of $30.3 million. Continued losses are a risk as Belite advances its drug programs, particularly if regulatory or development progress takes longer than expected. Belite Bio reveals $30.3 million quarterly loss

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on BLTE. Morgan Stanley increased their price target on shares of Belite Bio from $201.00 to $206.00 and gave the company an "overweight" rating in a report on Friday, August 14th. Cantor Fitzgerald upped their price objective on shares of Belite Bio from $266.00 to $270.00 and gave the company an "overweight" rating in a research report on Wednesday, August 12th. Benchmark reiterated a "buy" rating on shares of Belite Bio in a research note on Friday, August 14th. UBS Group restated a "buy" rating on shares of Belite Bio in a research note on Thursday, September 3rd. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $245.00 price target on shares of Belite Bio in a report on Thursday, October 15th. Eight research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $227.40.

Belite Bio Stock Up 9.0%

The business has a 50-day simple moving average of $161.02 and a two-hundred day simple moving average of $160.25. The stock has a market capitalization of $6.84 billion, a P/E ratio of -62.26 and a beta of -1.19.

Belite Bio (NASDAQ:BLTE - Get Free Report) last posted its earnings results on Thursday, November 12th. The company reported ($0.60) earnings per share for the quarter, topping the consensus estimate of ($0.79) by $0.19. On average, sell-side analysts forecast that Belite Bio, Inc. Sponsored ADR will post -3.08 earnings per share for the current year.

Insider Buying and Selling at Belite Bio

In other news, CFO Hao-Yuan Chuang sold 49,433 shares of the firm's stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $187.64, for a total transaction of $9,275,608.12. Following the completion of the sale, the chief financial officer owned 44,000 shares of the company's stock, valued at approximately $8,256,160. This trade represents a 52.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Yu-Hsin Lin sold 74,435 shares of the firm's stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $187.71, for a total transaction of $13,972,193.85. Following the sale, the chief executive officer directly owned 96,134 shares of the company's stock, valued at approximately $18,045,313.14. The trade was a 43.64% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 168,330 shares of company stock worth $31,969,118 over the last ninety days. Corporate insiders own 13.29% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in BLTE. State Street Corp increased its holdings in shares of Belite Bio by 6.9% in the third quarter. State Street Corp now owns 34,044 shares of the company's stock valued at $5,781,000 after purchasing an additional 2,196 shares in the last quarter. Alberta Investment Management Corp acquired a new position in Belite Bio during the 3rd quarter worth $4,076,000. Candriam S.C.A. bought a new position in Belite Bio in the 3rd quarter valued at $10,711,000. Vise Technologies Inc. bought a new position in Belite Bio in the 3rd quarter valued at $217,000. Finally, GAMMA Investing LLC boosted its position in Belite Bio by 5.0% in the 3rd quarter. GAMMA Investing LLC now owns 1,771 shares of the company's stock valued at $301,000 after buying an additional 85 shares during the last quarter. 0.53% of the stock is owned by institutional investors.

Belite Bio Company Profile

Belite Bio, Inc. is a clinical-stage biopharmaceutical company developing treatments for retinal and metabolic diseases. The company focuses on conditions with limited treatment options, including inherited retinal disorders and age-related eye disease. Its lead drug candidate, tinlarebant, is an oral therapy designed to reduce the accumulation of toxic vitamin A byproducts in the retina. Belite Bio is evaluating tinlarebant for Stargardt disease and geographic atrophy associated with dry age-related macular degeneration.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.